Rekvina Labs

Rekvina_Labs13 Dec 2021

Pharmaceuticals

₹

0.00 (0.00%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Rekvina Labs

Rekvina Labs

Pharmaceuticals

Rekvina_Labs13 Dec 2021

₹

0.00 (0.00%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
24-Mar-2014	S	Rekvina Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 24, 2014, inter alia, has transacted the following: 1. Approved sub-division of face value of Equity Shares. Every shareholder holding 1 (one) Equity share of Rs. 10/- each will be entitled to 2 (two) Equity Share of Rs. 5/- each. SUB. :- Sub Division of equity shares of Rekvina Laboratories Limited (Scrip Code 526075) Trading Members of the Exchange are hereby informed that Rekvina Laboratories Limited has fixed the Record Date for the purpose of sub division of equity shares of the company. DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT COMPANY NAME & CODE Rekvina Laboratories Limited (526075) RECORD DATE 02/05/2014 PURPOSE Sub Division of existing equity shares from every ONE equity share of Rs.10/- each into TWO equity shares of Rs.5/- each. SUB-DIVIDED PAID-UP VALUE Rs.5/- SUB-DIVIDED PAID-UP VALUE W.E.F. 30/04/2014 DR- 021/2014- 2015 Note :- i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route Scheme will be for Rs. 5/- paid up w.e.f. 30/04/2014. ii. ISIN No. INE092O01010 of Rs.10/- paid up will not be valid for transactions done on the Exchange on or after 30/04/2014. iii. The new ISIN Number for Rs.5/- paid up will be informed to the market by a separate notice. (As Per BSE Notice Dated on 21.04.2014)	02-May-2014
02-Feb-2024	BC	REKVINA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve 1. Standalone un-audited financia	12-Feb-2024
27-Oct-2023	BC	REKVINA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023 inter alia to consider and approve In Pursuant to Regulation 29 of the S	09-Nov-2023
06-Sep-2023	BC	Pursuant to above mentioned subject, Please find attached Notice of Annual General Meeting and Annual Report for the financial Year ended 2022-23. Proceeding/ Outcome of 35th Annual General Meetin	29-Sep-2023
30-Sep-2023	BC	Dear Sir/ Ma''am, With reference to the trail mail, we do hereby submit Scrutinizer''s Report of Rekvina Laboratories Limited for the financial year ended March 31, 2023.	29-Sep-2023
06-Sep-2023	BC	Pursuant to above mentioned subject, Please find attached Notice of Annual General Meeting and Annual Report for the financial Year ended 2022-23.	23-Sep-2023

No Rights has been declared by Rekvina_Labs

Book Closure

Record Date	Split Date	Purpose
12-Feb-2024	-	REKVINA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve 1. Standalone un-audited financia
09-Nov-2023	01 Jan'1900	REKVINA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023 inter alia to consider and approve In Pursuant to Regulation 29 of the S
29-Sep-2023	-	Pursuant to above mentioned subject, Please find attached Notice of Annual General Meeting and Annual Report for the financial Year ended 2022-23. Proceeding/ Outcome of 35th Annual General Meetin
29-Sep-2023	-	Dear Sir/ Ma''am, With reference to the trail mail, we do hereby submit Scrutinizer''s Report of Rekvina Laboratories Limited for the financial year ended March 31, 2023.
23-Sep-2023	01 Jan'1900	Pursuant to above mentioned subject, Please find attached Notice of Annual General Meeting and Annual Report for the financial Year ended 2022-23.

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Rekvina Labs Ltd ₹4.50(0.00/0.00%)	4.50	+0.00	2.71	7.91	0.00	875.03
Astrazeneca Pharma India Ltd ₹5,333.85(-7.40/-0.14%)	5,333.85	-7.40	13,334.63	67.79	83.60	20.36
Bliss GVS Pharma Ltd ₹129.20(+5.50/4.45%)	129.20	+5.50	1,352.61	67.42	19.82	1.38
Cipla Ltd ₹1,419.55(+18.35/1.31%)	1,419.55	+18.35	114,613.75	54.95	34.85	4.43
Amrutanjan Health Care Ltd ₹786.60(+88.65/12.70%)	786.60	+88.65	2,274.11	29.81	51.68	8.68
Abbott India Ltd ₹26,604.35(+188.60/0.71%)	26,604.35	+188.60	56,534.24	18.89	49.35	18.18

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	0.00	0.00	0.00	0.00	0.00	0.00
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	0.00	0.00	0.00	0.00	0.00	0.00
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Expenditure	0.00	0.01	0.00	0.00	0.00	0.00
PBIDT	0.00	-0.01	0.00	0.00	0.00	0.00
Interest	0.00	0.00	0.00	0.00	0.00	0.00
PBDT	0.00	-0.01	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Reported Profit After Tax	0.00	-0.01	0.00	0.00	0.00	0.00
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.00	-0.01	0.00	0.00	0.00	0.00

EPS (Unit Curr.)	-0.01	-0.01	0.00	0.00	0.00	-0.01
EPS (Adj) (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Calculated EPS (Unit Curr.)	-0.01	-0.01	0.00	0.00	0.00	-0.01
Calculated EPS (Adj) (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Calculated EPS (Ann.) (Unit Curr.)	-0.03	-0.05	0.00	0.00	0.00	-0.03
Calculated EPS (Adj) (Ann.) (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	3.01	3.01	3.01	3.01	3.01	3.01
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	5.00	5.00	5.00	5.00	5.00	5.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	0.00	0.00	0.00	0.00	0.00	0.00
PBDTM(%)	0.00	0.00	0.00	0.00	0.00	0.00
PATM(%)	0.00	0.00	0.00	0.00	0.00	0.00

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 18	Mar 17	Mar 16	Mar 15
SOURCES OF FUNDS :
Share Capital	3.01	3.01	3.01	3.01	3.01	3.01
Reserves Total	-3.00	-3.00	-2.61	-2.53	-2.51	-2.45
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	0.01	0.01	0.40	0.48	0.50	0.56
Secured Loans	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured Loans	0.08	0.00	0.21	0.17	0.01	0.01
Total Debt	0.08	0.00	0.21	0.17	0.01	0.01
Total Liabilities	0.09	0.01	0.61	0.65	0.51	0.57
APPLICATION OF FUNDS :
Gross Block	0.51	0.51	0.51	0.51	0.51	0.51
Less : Accumulated Depreciation	0.37	0.37	0.37	0.37	0.37	0.37
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	0.14	0.14	0.14	0.14	0.14	0.14
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	0.00	0.00	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.05	0.05	0.05	0.05	0.05	0.05
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	0.00	0.00	0.00	0.00	0.00	0.00
Sundry Debtors	0.00	0.00	0.26	0.25	0.28	0.25
Cash and Bank	0.01	0.00	0.15	0.13	0.03	0.00
Loans and Advances	0.00	0.00	0.16	0.17	0.10	0.17
Total Current Assets	0.01	0.00	0.57	0.56	0.41	0.43
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	0.11	0.18	0.19	0.13	0.13	0.09
Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Total Current Liabilities	0.11	0.18	0.19	0.13	0.13	0.09
Net Current Assets	-0.10	-0.18	0.38	0.42	0.28	0.34
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	0.00	0.00	0.00	0.00	0.00	0.00
Net Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	0.10	0.02	0.58	0.62	0.48	0.54
Contingent Liabilities	0.00	0.00	0.00	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2018	Mar 2017	Mar 2016
Cash and Cash Equivalents at Beginning of the year	0.00	0.00	0.13	0.03	0.00
Net Cash from Operating Activities	0.01	-0.04	-0.02	0.01	-0.04
Net Cash Used In Investing Activities	0.00	0.04	0.00	-0.07	0.07
Net Cash Used In Financing Activities	0.00	0.00	0.04	0.16	0.00
Net Inc./Dec In Cash And Cash Equivalents	0.01	0.00	0.01	0.10	0.03
Cash And Cash Equivalents At End Of The Year	0.01	0.00	0.15	0.13	0.03

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

45.09%

FII Shareholding

0.00%

DII Shareholding

0.00%

Public Shareholding

54.91%

**Promoter pledged shareholding 45.09%

About Rekvina Labs Ltd

Rekvina Labs Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 2.71 crores. It has reported a sales of Rs. 0 crores and a net profit of Rs. 0 crores for the quarter ended December 2018. The company management includes , Mukesh Jamnadas Shah,Amit Mukeshbhai Shah,Vibha Mukesh Shah,Mahendra Shantilal Dalal,Jitendra Laljibhai Doshi,Bhavesh Vora (Rekvina Labs Ltd) among others.

Chairman

Registered office

328 Paradise Complex,Sayajigunj,Vadodara,Gujarat,390005

FAX :

Background

Incorporation Year1988

Face Value₹5

Market Lot1

How to buy Rekvina Labs shares on nse?

To buy Rekvina Labs shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Rekvina Labs share price today?

The Rekvina Labs shares price on nse is Rs.4.5 today.

What is the market cap of Rekvina Labs shares on BSE ?

The company has a market capitalization of Rs.2.71Cr

What is the PE & PB ratio of Rekvina Labs shares ?

PE is 0 and PB is 875.03

What is the 52 Week High and Low of Rekvina Labs shares?

Rekvina Labs stock price high: Rs.4.5 Rekvina Labs stock price low: Rs.0